Full-Time

Director – National Accounts

Pharmaceuticals

Posted on 5/12/2026

Asahi Kasei Corporation

Asahi Kasei Corporation

10,001+ employees

Diversified chemicals, materials, healthcare, housing conglomerate

Compensation Overview

$220k - $250k/yr

Remote in USA

Hybrid

Category
Sales & Account Management (1)
Required Skills
Forecasting
Data Analysis
Requirements
  • Bachelor's degree required.
  • Minimum eight+ years pharmaceutical/biotech experience in PBM/Payer space with at least three years of experience managing NAM teams.
  • Deep understanding and knowledge of the managed market dynamics, payer/PBM economics, and the key issues/shifts changing the US healthcare landscape. Proficiency in VA/DOD and Medicaid preferred.
  • Demonstrated ability to work collaboratively with and influence senior leaders and peers.
  • Excellent communication skills, both verbal and written.
  • Established relationships with Pharmacy Directors, Medical Directors, and other key personnel at key payer accounts.
  • Demonstrated knowledge of payer decision-making for formulary processes, coverage, coding, billing, pathway development, and patient access to medicines.
  • Demonstrated ability to develop, communicate, and implement successful strategic initiatives.
  • Strong business acumen. Experience in negotiating contracts and agreements. Experience with value based contracting in an orphan drug or specialty space desired.
  • Strong leadership skills, taking ownership in work streams, and exercising influence in the decision-making process among diverse functional and geographical areas and at all levels of management, with the ability to customize to market needs.
  • Proven ability in successfully managing complexity across multi-functional stakeholders and building strong relationships.
  • Travel Requirements: ~30% (national)
Responsibilities
  • Responsible for the development of the Company’s strategy and overseeing all Payer (PBM, Medicare, Commercial, Medicaid and Federal Channel) access to the Company’s portfolio of products with the goal of removing payer restrictions and securing appropriate access aligned with our FDA approved label.
  • Accountable for all resources and training needs to support the team and broader department, as necessary. Responsible for all projects and vendor support aligned with the PBM/Payer space in all channels from a strategic and tactical perspective.
  • Create and execute customer specific strategies and tactics to support appropriate formulary placement and reimbursement across payer customers that lead to profitable access.
  • Negotiate cost-effective, profitable contracts and terms where appropriate that allow access to Company products within established product pricing policy, GTN guidance, and approved by pricing committee. Responsible for all analytics and contract analysis as well as business case proposals aligned with all contracting opportunities, while also monitoring contracts for continued value, renegotiating as appropriate through the contract lifecycle.
  • Optimize the product’s formulary positioning and increase product market share via leadership of collaborative pull-through initiatives with field sales and brand marketing. Routinely review data (sales, trends, comparison etc.) to identify pull-through opportunities, and work with sales leadership team to execute on aligned pull-through plans.
  • Develop strong relationships with all trading partners including GPO/PBM/Payer in all channels including but not limited to Commercial, Medicare, Medicaid/340B and Federal Channel VA/DOD. This includes timely interactions and QBR for all contracted and identified key accounts and Semi-Annual for all regional accounts.
  • Become an expert on the assigned payer’s overall business models to understand clients and areas where their access landscape has variances in their membership. Build relationships with the cross functional team at all assigned accounts.
  • Educate field team on payer access landscape and identifies criteria for coverage with PBMs that have the largest life coverage on their respective national formularies.
  • Coordinate with Field Access teams, Sales team, Marketing (including Market Access Marketing), and Commercial Operations to ensure that team members understand the overall access/reimbursement strategy. Support field questions or issues that arise and provide solutions. Work with Market Access Marketing to create any field collateral needed to support education and awareness around Company product access.
  • Share internally key market trends/observations, best practices, and customer learnings to support the development and/or refinement of strategies and tactics. Serve as the internal subject matter expert for Company on all US payer dynamics.
  • Conduct all business in accordance with company compliance guidelines and ensure compliance with relevant laws and regulatory mandates.
  • Identify and cultivate new opportunities within the PBM/GPO/Payer/Govt. channels to expand market presence and improve commercial outcomes.
  • Direct management of NAM team in support of all PBM/Payer activities.
  • Responsible for all leadership communication as it relates to PBM/Payer access and contracting, managing all GTN impact and working with finance on all forecasting impact.
Asahi Kasei Corporation

Asahi Kasei Corporation

View

Asahi Kasei produces a wide range of products including performance polymers, medical devices, and residential construction materials. The company operates by applying polymer science and engineering to create specific components, such as battery separators for electric vehicles and dialysis equipment for patient care. Unlike many specialized competitors, Asahi Kasei maintains a highly diversified portfolio that spans from basic chemicals to advanced healthcare, allowing it to balance industrial stability with growth in emerging technology sectors. Its goal is to drive global expansion and sustainability by developing materials and services that support carbon neutrality, clean energy, and community health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1922

Simplify Jobs

Simplify's Take

What believers are saying

  • $920M Aicuris acquisition expands viral therapeutics for immunocompromised patients.
  • North Carolina Hipore facility targets EV and AI data center separator demand.
  • Nippon Steel titanium recycling boosts chlor-alkali circular economy advantages.

What critics are saying

  • EV slowdown delays Canada plant to 2029, slashing 2030 forecast to 2M vehicles.
  • Toray erodes US separator share with faster ramps and lower costs.
  • SK IE undercuts coated separator pricing by 15-20% in North America.

What makes Asahi Kasei Corporation unique

  • Asahi Kasei develops PFAS-free PA66 polyamide for low-friction automotive applications.
  • Asahi Kasei pioneers continuous carbon fiber recycling from CFRP pressure vessels.
  • Asahi Kasei deploys Aqualyzer-C electrolyzer for cold-climate hydrogen production.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Asahi Kasei Corporation who can refer or advise you

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 10th, 2026
Asahi Kasei builds $200M+ US battery separator plant to tap EV boom

Asahi Kasei is expanding its battery separator production in the US with a new Hipore coating facility in North Carolina, targeting growing electric vehicle and energy storage demand. The facility, set to start production in mid-2027, will focus on advanced separator technologies aligned with regional safety standards. The move positions Asahi Kasei closer to North American battery and EV manufacturers, targeting higher-value coated separator products. Shares in TSE:3407 are trading at ¥1,634.5, with a year-to-date return of 15.1% and 78.1% over the past year. The expansion faces execution risks including potential delays and cost overruns, alongside competitive pressure from rivals like Toray, Sumitomo Chemical and SK IE Technology. Financial impact is expected to be phased, allowing time for customer qualification and contract negotiations.

Business Wire
Mar 20th, 2026
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO

KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, B...

Scaffmag Ltd
Mar 19th, 2026
KEWAZO raises $30M to scale lifting robots across industrial sites

KEWAZO, a Munich and Houston-based robotics company, has raised $30 million to expand its lifting robot technology across global industrial sites. The funding round was backed by Chevron Technology Ventures, Asahi Kasei, Schooner Capital and existing investors. The company's flagship product, LIFTBOT, automates vertical material movement and is already operational at over 20 industrial locations across Europe and North America, including refineries, petrochemical plants and power facilities. The technology replaces cranes and manual handling during maintenance and capital projects. Chief executive Artem Kuchukov said demand is driven by the need for practical automation in live industrial environments. The funding will support increased deployment capacity and expansion into additional workflows. KEWAZO is also developing a data platform to improve operational transparency and support further automation.

Business Wire
Mar 18th, 2026
Asahi Kasei, Nippon Steel launch pure titanium recycling for electrolysis cells

Asahi Kasei, Nippon Steel and Nippon Steel Trading have launched a recycling initiative to convert pure titanium scrap from electrolysis cell manufacturing into raw material for new pure titanium. The collaboration aims to reduce environmental impact and enhance material value recovery in the chlor-alkali industry. Pure titanium is used in electrolysis cells' anode side to resist corrosive chlorine, requiring extremely high purity. Asahi Kasei controls the entire process at its Nobeoka site through digital tools to prevent contamination. Nippon Steel Trading collects and processes the scrap, which Nippon Steel then remelts into new pure titanium. The partners plan to increase recycling rates and extend the initiative to other metals used in electrolysis cells, building on Asahi Kasei's precious metals recycling project announced in April 2025.

Business Wire
Mar 12th, 2026
Asahi Kasei installs 1MW electrolyzer at Finland's first commercial hydrogen refueling station

Asahi Kasei has begun installing a containerised 1 MW-class alkaline-water electrolyzer at Finland's first commercial hydrogen refueling station in Jyväskylä. The Aqualyzer-C system will be operated by Cefmof Hydrogen, a subsidiary of the Central Finland Mobility Foundation, with operations scheduled to start in summer 2026. The electrolyzer will produce 400kg of hydrogen daily, sufficient to refill approximately three fuel cell vehicles per hour. The project will support local hydrogen-powered transportation, including fuel cell vehicles and hydrogen buses, and serve as a model for hydrogen utilization in cold climates. Asahi Kasei, which has over 50 years of experience in large-scale industrial electrolysis, added the 1–7.5 MW Aqualyzer-C range to its portfolio in 2024 to meet diverse customer needs across small and large-scale hydrogen projects.